Jounce Therapeutics Inc (JNCE) Expected to Post Quarterly Sales of $15.64 Million

Analysts expect Jounce Therapeutics Inc (NASDAQ:JNCE) to announce sales of $15.64 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Jounce Therapeutics’ earnings. The lowest sales estimate is $15.00 million and the highest is $16.27 million. Jounce Therapeutics reported sales of $20.29 million during the same quarter last year, which indicates a negative year over year growth rate of 22.9%. The company is scheduled to report its next earnings report on Friday, March 9th.

According to Zacks, analysts expect that Jounce Therapeutics will report full-year sales of $15.64 million for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post sales of $88.96 million per share, with estimates ranging from $74.92 million to $103.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.12. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. The business had revenue of $18.10 million for the quarter, compared to analysts’ expectations of $20.00 million. Jounce Therapeutics’s revenue was up 7.1% on a year-over-year basis.

A number of brokerages have recently commented on JNCE. Zacks Investment Research raised shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, January 3rd. Robert W. Baird restated a “buy” rating and issued a $30.00 target price on shares of Jounce Therapeutics in a research note on Friday, November 10th. Finally, JPMorgan Chase & Co. set a $28.00 target price on shares of Jounce Therapeutics and gave the company a “buy” rating in a research note on Monday, November 13th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Jounce Therapeutics currently has an average rating of “Buy” and a consensus target price of $24.00.

In other news, Director Barbara Gayle Duncan sold 4,000 shares of Jounce Therapeutics stock in a transaction on Friday, January 26th. The shares were sold at an average price of $25.00, for a total transaction of $100,000.00. Following the completion of the sale, the director now directly owns 4,000 shares in the company, valued at $100,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameriprise Financial Inc. boosted its position in shares of Jounce Therapeutics by 45.2% in the third quarter. Ameriprise Financial Inc. now owns 184,243 shares of the company’s stock worth $2,871,000 after acquiring an additional 57,335 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Jounce Therapeutics by 123.8% in the 2nd quarter. Vanguard Group Inc. now owns 255,060 shares of the company’s stock valued at $3,578,000 after purchasing an additional 141,096 shares during the last quarter. Alyeska Investment Group L.P. increased its position in shares of Jounce Therapeutics by 43.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 262,105 shares of the company’s stock valued at $4,084,000 after purchasing an additional 79,683 shares during the last quarter. Conning Inc. increased its position in shares of Jounce Therapeutics by 36.0% in the 3rd quarter. Conning Inc. now owns 125,960 shares of the company’s stock valued at $1,962,000 after purchasing an additional 33,350 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of Jounce Therapeutics by 71.8% in the 3rd quarter. Nationwide Fund Advisors now owns 20,523 shares of the company’s stock valued at $320,000 after purchasing an additional 8,577 shares during the last quarter. Institutional investors own 47.40% of the company’s stock.

Shares of Jounce Therapeutics (NASDAQ:JNCE) traded down $0.61 during trading hours on Thursday, hitting $23.37. 237,032 shares of the stock were exchanged, compared to its average volume of 348,449. The stock has a market capitalization of $753.59 and a price-to-earnings ratio of -111.29. Jounce Therapeutics has a fifty-two week low of $11.05 and a fifty-two week high of $29.29.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/04/jounce-therapeutics-inc-jnce-expected-to-post-quarterly-sales-of-15-64-million.html.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply